Sangui Biotech International Inc (SGBI) financial statements (2022 and earlier)
Company profile
| Business Address |
352 SOUTH 200 WEST FARMINGTON, UT 84025 |
| State of Incorp. | CO |
| Fiscal Year End | June 30 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2021 Q2 | 9/30/2021 Q1 | 6/30/2021 Q4 | 3/31/2021 Q3 | 12/31/2020 Q2 | 9/30/2020 Q1 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 8 | 13 | 30 | 12 | 9 | 21 | ||
| Cash and cash equivalents | 8 | 13 | 30 | 12 | 9 | 21 | ||
| Receivables | 31 | 24 | 23 | 27 | 15 | 34 | ||
| Prepaid expense | 16 | 9 | 12 | 15 | 14 | 10 | ||
| Other undisclosed current assets | 3 | 2 | 1 | 2 | 1 | |||
| Total current assets: | 56 | 49 | 67 | 55 | 41 | 66 | ||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 1 | 1 | 1 | 1 | 2 | 2 | ||
| Other undisclosed noncurrent assets | 78 | 85 | 66 | 70 | 79 | 81 | ||
| Total noncurrent assets: | 79 | 86 | 67 | 72 | 81 | 83 | ||
| TOTAL ASSETS: | 135 | 135 | 134 | 126 | 121 | 149 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Debt | 767 | 746 | 753 | 746 | 740 | 679 | ||
| Due to related parties | 69 | 66 | 62 | 57 | 55 | 48 | ||
| Other liabilities | 1 | |||||||
| Other undisclosed current liabilities | 147 | 157 | 140 | 149 | 146 | 164 | ||
| Total current liabilities: | 984 | 968 | 955 | 952 | 940 | 892 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 53 | 58 | 55 | 57 | 63 | 63 | ||
| Operating lease, liability | 53 | 58 | 55 | 57 | 63 | 63 | ||
| Other undisclosed noncurrent liabilities | (53) | (58) | (55) | (57) | (63) | (63) | ||
| Total noncurrent liabilities: | 53 | 58 | 57 | 63 | 63 | |||
| Total liabilities: | 1,037 | 1,027 | 1,009 | 1,010 | 1,003 | 955 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | (250) | (239) | (224) | (233) | (233) | (158) | ||
| Common stock | 33,100 | 33,100 | 33,088 | 33,028 | 33,028 | 33,028 | ||
| Treasury stock, value | (19) | (19) | (19) | (19) | (19) | (19) | ||
| Additional paid in capital | 4,513 | 4,513 | 4,513 | 4,513 | 4,513 | 4,513 | ||
| Accumulated other comprehensive income | 89 | 89 | 90 | 90 | 91 | 91 | ||
| Accumulated deficit | (37,932) | (37,922) | (37,895) | (37,845) | (37,845) | (37,771) | ||
| Stockholders' equity attributable to noncontrolling interest | (653) | (653) | (652) | (650) | (649) | (648) | ||
| Total stockholders' equity: | (902) | (892) | (875) | (883) | (882) | (806) | ||
| TOTAL LIABILITIES AND EQUITY: | 135 | 135 | 134 | 126 | 121 | 149 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2021 Q2 | 9/30/2021 Q1 | 6/30/2021 Q4 | 3/31/2021 Q3 | 12/31/2020 Q2 | 9/30/2020 Q1 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 22 | 19 | 14 | 21 | 11 | 20 | |
| Gross profit: | 22 | 19 | 14 | 21 | 11 | 20 | |
| Operating expenses | (42) | (62) | (54) | (50) | (49) | (64) | |
| Operating loss: | (20) | (44) | (40) | (28) | (38) | (44) | |
| Nonoperating income (expense) | 10 | 16 | (12) | 28 | (37) | (32) | |
| Foreign currency transaction gain (loss), before tax | 14 | 20 | (7) | 32 | (32) | (27) | |
| Interest and debt expense | (9) | (5) | (5) | (5) | (4) | (4) | |
| Loss before gain (loss) on sale of properties: | (20) | (33) | (56) | (5) | (80) | (80) | |
| Other undisclosed net income | 9 | 5 | 5 | 5 | 4 | 4 | |
| Net loss: | (10) | (28) | (52) | (1) | (75) | (76) | |
| Other undisclosed net income attributable to parent | 0 | 1 | 2 | 1 | 1 | 1 | |
| Net loss available to common stockholders, diluted: | (10) | (27) | (50) | (0) | (74) | (75) | |
Comprehensive Income ($ in thousands)
| 12/31/2021 Q2 | 9/30/2021 Q1 | 6/30/2021 Q4 | 3/31/2021 Q3 | 12/31/2020 Q2 | 9/30/2020 Q1 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (10) | (28) | (52) | (1) | (75) | (76) | |
| Other comprehensive income | 11 | 28 | 53 | 1 | 76 | 76 | |
| Comprehensive income, net of tax, attributable to parent: | 0 | 0 | 1 | 0 | 1 | 0 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.